Erectile Dysfunction Clinical Trial
Official title:
Clinical Trial With Random Assignment to Evaluate the Efficacy and Safety of Radial Waves for the Treatment of Erectile Dysfunction
Objective: To evaluate the efficacy and safety of radial shock waves for the treatment of
erectile dysfunction [ED].
Patients and methods: Randomized, double-blind clinical trial. The study will include
patients of legal age with diagnosis of ED and score on the International Index of Erectile
Function [IIEF-EF] scale between 11 and 21 points, who voluntarily decide to participate and
sign the informed consent. Patients with bladder cancer, prostate cancer or active colon, ED
of psychological origin, any psychiatric disorder, spinal cord injury, clinical suspicion of
hypogonadism (score on the Aging Males' Symptoms scale greater than 36), infections or active
lesions of the penis or pubic area, ED secondary to treatment with medications
(antiandrogenic therapy, use of corticosteroids, anti-Parkinson's, antipsychotics), radical
prostatectomy or other radical pelvic surgery, history of pelvic radiotherapy, penile
implantation, or endocrine diseases that occur with ED (acromegaly, gigantism, Addison's
disease, hyperprolactinemia, androgenic deficiency), sickle cell anemia, and anticoagulated
patients will be excluded.
Patients will be randomly assigned to one of the following treatment arms:
- Arm 1 (Standard treatment (oral sildenafil) + Radial wave therapy)
- Arm 2 (Standard treatment (oral sildenafil) + Placebo therapy)
Measurements will be made of the Erection Hardness Score [EHS] and IIEF-EF scale scores, of
the use of medication and of the possible adverse events of the therapy, at the beginning and
end of the treatment, and one month after the therapies are finished.
Background: Radial shock waves are an effective therapy for the management of various
problems at the muscular and joint level, thanks to the effect it has on the activation of
microcirculation. The effect of these waves on patients with erectile dysfunction is
currently unknown; however, it is considered possible to help recovery in patients with
vascular origin dysfunction by increasing microcirculation blood flow in this area.
Objective: To evaluate the efficacy and safety of radial shock waves for the treatment of
erectile dysfunction.
Patients and methods: Randomized, double-blind clinical trial. The study will include
patients of legal age with diagnosis of ED and score on the IIEF-EF scale between 11 and 21
points, who voluntarily decide to participate and sign the informed consent. Patients with
bladder cancer, prostate cancer or active colon, ED of psychological origin, any psychiatric
disorder, spinal cord injury, clinical suspicion of hypogonadism (AMS greater than 36),
infections or active lesions of the penis or pubic area, ED secondary to treatment with
medications (antiandrogenic therapy, use of corticosteroids, anti-Parkinson's,
antipsychotics), radical prostatectomy or other radical pelvic surgery, history of pelvic
radiotherapy, penile implantation, or endocrine diseases that occur with ED (acromegaly,
gigantism, Addison's disease, hyperprolactinemia, androgenic deficiency), sickle cell anemia,
and anticoagulated patients will be excluded.
Patients will be randomly assigned to one of the following treatment arms:
- Arm 1 (Standard treatment (oral sildenafil) + Radial wave therapy): Sildenafil according
to the degree of patient involvement + 6 sessions of radial waves. A weekly session of
radial waves will be applied with the following parameters: 6000 pulses at 1.5-2.6 bar
(depending on patient tolerance), with a frequency of 17Hz, the frequency should
increase to 22HZ the first 500 impulses to create mild anesthesia in the area; in all
radial wave sessions, 4000 impulses will be distributed in the body of the penis in
scanning technique and 2000 impulses in the perineal area.
- Arm 2 (Standard treatment (oral sildenafil) + Placebo therapy): Sildenafil according to
the patient's degree of affectation + 6 sessions of placebo therapy. There will be a
weekly session of placebo wave therapy, using the respective device to prevent the
patient from receiving the radial wave. The same parameters of the "real" therapy will
be used: 6000 pulses at 2.6 bar, with a frequency of 17 Hz; in all radial wave sessions,
4000 impulses will be distributed in the body of the penis in scanning technique and
2000 impulses in the perineal area.
Measurements will be made of the EHS and IIEF-EF scale scores, of the use of medication and
of the possible adverse events of the therapy, at the beginning and end of the treatment, and
one month after the therapies are finished.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
| Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
| Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
| Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
| Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
| Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
| Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
| Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
| Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
| Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
| Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
| Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
| Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
| Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
| Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
| Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
| Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
| Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 | |
| Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 | |
| Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 |